Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herpes Claim Emerges As Latest FDA/FTC Joint Enforcement Target

This article was originally published in The Tan Sheet

Executive Summary

Strictly Health Corp. makes claims on its websites and in social media postings for its dietary supplements including, “incredible remedy is an advanced and multifaceted herpes treatment that overwhelms and keeps the virus sealed and subdued.”

You may also be interested in...



Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements

FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola. One firm’s website offers a video titled, “Urgent Message to Ebola-Stricken Nations' Heads of State,” and another claims “primary uses for oregano include athlete’s foot, candida, canker sores, Ebola virus.”

Investors Go Beserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel